United States Pharmaceutical Sector Report (2011 Edition)

United States Pharmaceutical Sector Report (2011 Edition)


July 1, 2011
73 Pages - SKU: SYGR6504952
License type:
Online Download      US $550.00
Global Site License      US $900.00
Countries covered: United States

United States is world’s largest spender on healthcare at an estimated 16% of GDP in 2010. This spending is likely to continue to grow at a faster pace in the light of healthcare reforms of 2010 that extended insurance to around 45.7 million residents. United States is the single largest pharmaceutical market globally, accounting for more than 40% of the world's pharmaceutical sales. Over the past two years, however, the U.S. pharmaceutical industry has faced a number of macroeconomic challenges and industry specific issues such as inflation, government healthcare policy, declining levels of innovation, patent losses, among others. The pharmaceutical market in United States is estimated at US$338 billion, growing at 2.5% since 2009 and at a CAGR of 4.5% since 2004. Prescription drugs account for the largest share (88.6%) of total pharmaceutical sales followed by OTC drugs (8.2%) and Alternative Medication (3.2%).

Synergyst’s “United States Pharmaceutical Sector Report (2011 Edition)” is a comprehensive assessment of to the U.S. pharmaceutical market and the trends that are prevailing in the market. Report analyses healthcare, economic and policy environment in the country and presents the SWOT analysis of the country’s pharmaceutical sector. Dynamics of the industry are presented by evaluating the industry structure and estimation of market size, both in terms of volume and dollar value. Market sizing and forecast is provided for the overall market and all the segments from 2005 to 2015. Report also looks at trends that are impacting the pharmaceutical sales in United States and assess the competitive landscape in the industry.



More United States Prescription Drugs reports

Physician Views: Life-cycle management strategies in multiple sclerosis – can new versions of Copaxone, Avonex drive market share retention? by FirstWord
Physician Views: Life-cycle management strategies in multiple sclerosis – can new versions of Copaxone, Avonex drive market share retention? Scope With ...
United States Pharmaceuticals and Healthcare Report Q2 2014 by Business Monitor International
United States Pharmaceuticals and Healthcare Report Q2 2014BMI View: Pharmaceutical companies are facing far greater opportunities and challenges thanthe Affordable Care Act (ACA). Healthcare reform ...
PharmaPoint: Schizophrenia - US Drug Forecast and Market Analysis to 2022 by GlobalData
PharmaPoint: Schizophrenia - US Drug Forecast and Market Analysis to 2022SummarySchizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core ...
Pharmacies and Drug Stores Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2020, NAIC 446110 by Plunkett Research, Ltd.
Pharmacies and Drug Stores Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2020, NAIC 446110Vital industry-specific data including metrics, benchmarks, historic numbers, ...
See all reports like this >>

More United States reports

The 2013-2018 Outlook for Collagen and (hyaluronic Acid) HA-Based Biomaterials in the United States by Icon Group International, Inc.
The 2013-2018 Outlook for Collagen and (hyaluronic Acid) HA-Based Biomaterials in the United StatesThis econometric study covers the latent demand outlook for collagen and (hyaluronic ...
The 2013-2018 Outlook for Relish in the United States by Icon Group International, Inc.
This econometric study covers the latent demand outlook for relish across the states and cities of the United States. Latent demand (in millions of U.S. ...
The 2013-2018 Outlook for Indian Breads in the United States by Icon Group International, Inc.
This econometric study covers the latent demand outlook for Indian breads across the states and cities of the United States. Latent demand (in millions of ...
D&B Country RiskLine Report: The United States of America by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
See all reports like this >>